Abstract
Background The vaccines developed in 2020-2021 against the SARS-CoV-2 virus were designed to prevent severity and deaths due to COVID-19. However, estimates of the effectiveness of vaccination campaigns in achieving these goals remain a methodological challenge. In this work, we developed a Bayesian statistical model to estimate the number of deaths and hospitalisations avoided by vaccines in older adults in Brazil.
Methods We fit a linear model to predict the number of deaths and hospitalisations in older adults as a function of vaccination coverage and of casualties in younger adults. We then used this model to perform counterfactual analysis, simulating alternative scenarios without vaccination or with earlier vaccination roll-out. We estimated direct effects of COVID-19 vaccination by computing the difference between hypothetical and realised scenarios.
Results We estimated that more than 165 thousand individuals above 60 y.o. were not hospitalised due to COVID-19 in the first seven months of the vaccination campaign. An additional contingent of 100 thousand hospitalisations could have been avoided if vaccination had started earlier. We also estimated that more than 75 thousand lives were saved by vaccination in the period analysed for the same age group, and that additional 48 thousand lives could have been saved had the Brazilian Government started the vaccination programme earlier.
Conclusions Our estimates provide a lower bound for vaccination impacts in Brazil, demonstrating the importance of preventing suffering and loss of the older adults Brazilians. Once vaccines were approved, an early vaccination roll-out could have saved many more lives, especially when facing a pandemic.
Key messages
The coronavirus pandemic affected more severely older adults, which presented the higher rates of hospitalisation and deaths related to COVID-19, leading most countries, as Brazil, to start the vaccination following a decreasing age scheme.
Evaluating a hypothetical scenario of the absence of vaccines, we estimated the number of hospitalisations and deaths that Brazil has prevented due to the vaccination roll-out applied to persons above 60 years old: ≈167,000 hospitalisations did not occur and ≈77,000 lives were saved due to the vaccines.
The estimates for the number of lives saved and the avoided hospitalisations are a lower bound for the actual number because only the direct effects for the older adults were taken into account, and no herd immunity effect was considered.
Evaluating another hypothetical scenario, considering an eight weeks earlier rollout, Brazil could have saved a minimum of additional ≈48,000 lives and avoided another ≈100,000 hospitalisations compared to what happened.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors thank the research funding agencies: the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior -- Brazil (Finance Code 001 to FMDM and LSF), Conselho Nacional de Desenvolvimento Científico e Tecnológico -- Brazil (grant number: 315854/2020-0 to MEB, 141698/2018-7 to RLPS, 313055/2020-3 to PIP, 311832/2017-2 to RAK), Fundação de Amparo à Pesquisa do Estado de São Paulo -- Brazil (contract number: 2016/01343-7 to RAK), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro -- Brazil (grant number: E-26/201.277/2021 to LSB) and Inova Fiocruz/Fundação Oswaldo Cruz -- Brazil to LSB. The funding agencies had no role in the conceptualization of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated discussion. New color for figures. New supplementary figures.
Data Availability
All data and code used in this work is publicly available at https://github.com/covid19br/ bayes-vacina-paper.
